imiquimod has been researched along with Pseudomonas Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fung, MA; Opene, C; Silverstein, M | 1 |
| Aljuffali, IA; Fang, JY; Huang, CW; Lee, WR; Lin, YK; Shen, SC | 1 |
2 other study(ies) available for imiquimod and Pseudomonas Infections
| Article | Year |
|---|---|
Orf progressiva: giant progressive and destructive infections in the immunocompromised.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Ciprofloxacin; Debridement; Drug Therapy, Combination; Ecthyma, Contagious; Humans; Imiquimod; Immunocompromised Host; Kidney Transplantation; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Superinfection; Valacyclovir | 2021 |
Non-ablative fractional laser assists cutaneous delivery of small- and macro-molecules with minimal bacterial infection risk.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Aminoquinolines; Animals; Dextrans; Drug Delivery Systems; Fluorescein; Fluorescein-5-isothiocyanate; Imiquimod; Lasers, Solid-State; Mice, Inbred BALB C; Mice, Nude; Peptides; Pseudomonas aeruginosa; Pseudomonas Infections; Quantum Dots; Skin; Skin Absorption; Staphylococcal Infections; Staphylococcus aureus; Swine; Tretinoin | 2016 |